Treatment with miR-21 inhibitor suppresses TGF-β signaling, reduces fibrosis, and attenuates EndoMT in murine SSc models, whereas miR-155 inhibitor is linked with reduced inflammatory gene expression and vascular remodeling and dual effects on immune and vascular compartments [191,192,193]. Here, TGFB1 is linked to systemic sclerosis.